



 **MicroVention<sup>®</sup>**  
**TERUMO**

*Jan. 22, 2019*

# Our Mission

*MicroVention's mission is to be a leader in the creation of innovative neuroendovascular technologies that provide a meaningful improvement in patient lives.*

# Solutions in All Disease States



**Aneurysm  
Therapy**

**Ischemic Stroke &  
Carotid Artery Disease**

**Neurovascular  
Malformations**

**Access Product  
Solutions**




# MicroVention's Story



1997



**MicroVention® Begins**  
MicroVention® is Founded  
in Aliso Viejo, California



2003

**The 1<sup>st</sup> Generation HydroCoil®  
Embolic System is Launched**




2006

**MicroVention® is Acquired**  
Terumo Corporation  
acquires MicroVention®

2002

**MicroVention® Launches  
its 1<sup>st</sup> Products**


- MicroPlex® Coil System
- Complex® Helical Coil System
- HydroLink® Detachment System



2005

**MicroVention® Launches the  
First Instant Detachment System**

- V-Trak® Delivery System
- V-Grip® Detachment Controller
- HyperSoft® Platinum Coils



# Stronger Together

## Founded in 1921

Global Headquarters in  
Tokyo, Japan



- Cardiac and Vascular
- General Hospital
- Blood Management


## Founded in 1997

Global Headquarters in  
Aliso Viejo, California



- Neurovascular Focus
- Rapid R&D Innovation
- Clinical Outcomes Oriented
- Autonomous Business Unit

# Continuous Growth



# Advancing Technology



- Clear Track Record of Innovation
- Dedicated to Expanding Fast-Growth Opportunities

Complimentary Teams



- First to Market Intracascular Devices
- Deep Technical Expertise in Braiding
- Rigorous Clinical Data Support


Entrepreneurial Cultures

Focus on Innovation

# MicroVention® Today



**MicroVention® launches**  
WEB® 17 intrasaccular device



**2018**


**MicroVention® receives**  
PMA approval for LVIS® and  
LVIS® Jr. coil assist stents

**2017**

**MicroVention® expanded** with a  
new Worldwide Innovation Center  
in Aliso Viejo, California



**The GREAT & HEAT studies** showed that  
Hydrogel Coils provide less major recurrence  
and lower retreatment rates compared to  
platinum coils with an equal safety profile.<sup>1,2</sup>



**MicroVention® receives** PMA approval for  
the WEB® Aneurysm Embolization  
System, the first to market intrasaccular  
technology in the U.S.




1. Taschner CA. et al. Second-Generation Hydrogel Coils for the Endovascular Treatment of Intracranial Aneurysms - A Randomized Controlled Trial. Stroke 2018; 49: 667-674.  
2. Bendok, B. "New Generation Hydrogel Endovascular Aneurysm Treatment Trial (HEAT)." 2018 SNIS 15<sup>th</sup> Annual Meeting Late Breaking Abstract Presentation.



# The Future of MicroVention®

MicroVention® will continue to develop and commercialize innovative neuroendovascular technologies that provide a meaningful improvement in patient lives around the world.





*Thank You!  
Questions?*

